ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS reported Q2 2026 financial results with a net loss of $11.7 million ($1.28 per share), highlighting a strengthened balance sheet with $53.4 million in cash following a January private placement. The company announced positive blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, showing zero cases of ARIA-E and favorable trends in key biomarkers plasma pTau217 and CSF MTBR-tau243.
Key figures
- Net loss
- 11700000
- Ar status
- Zero cases of ARIA-E
- Cash position
- 53400000
- Ptau217 decline
- 15%
- Csf mtbr tau243 decline
- 13.3%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.